Cargando…
Tamoxifen induction of angiogenic factor expression in endometrium
Tamoxifen is the current therapy of choice for patients with oestrogen receptor positive breast cancer, and it is currently under evaluation as a prophylactic for women at high risk of developing the disease. However, tamoxifen is also known to induce proliferative changes in the endometrium increas...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375303/ https://www.ncbi.nlm.nih.gov/pubmed/11875740 http://dx.doi.org/10.1038/sj.bjc.6600157 |